Causal Localization via Mediation Analysis

• The paper presents a novel framework that decomposes the total causal effect into controlled direct effects and scaled indirect effects, pinpointing the impact of individual mediators.
• It employs robust estimation strategies like augmented inverse probability weighting and cross-fitting to adjust for confounders and mitigate model misspecification.
• The approach enables practical mediator ranking for targeted interventions by avoiding cross-world counterfactuals and offering experimentally actionable insights.

Causal localization via mediation analysis refers to a rigorous approach for decomposing the total causal effect of an exposure (or treatment) on an outcome into pathway-specific contributions of individual mediators, under identification conditions that support actionable, interpretable, and experimentally relevant inferences. The central objective is to enable the scientific or clinical investigator to determine which mediator (or mediators) is most responsible for transmitting the effect from exposure to outcome, thereby informing the design of efficient and targeted interventions.

1. Definitions and Formal Framework

Causal localization in mediation analysis is built on a potential outcomes framework with multiple manipulable mediators. Let $A$ denote the exposure, $Y$ the outcome, $L$ measured covariates, and $M_1,\ldots,M_K$ the $K$ candidate mediators. The essential estimands are:

• Total Effect (TE):

$\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$

where $Y(a)$ is the potential outcome if exposure is set to $A=a$.

• Controlled Direct Effect (CDE$_k(m)$):

$$\mathrm{CDE}_k(m) = \mathbb{E}[Y(1, M_k = m) - Y(0, M_k = m)],$$

with $Y$0 denoting the potential outcome if $Y$1 and the $Y$2-th mediator is set to $Y$3 (all other mediators left at their natural response to $Y$4).

• Controlled Indirect Effect (CIE$Y$5):

$Y$6

which quantifies the effect on $Y$7 of changing $Y$8 from 0 to 1 while holding $Y$9 fixed.

• Scaled Controlled Indirect Effect (sCIE$L$0):

$L$1

ensuring the decomposition:

$L$2

for each $L$3 (Sun et al., 2020).

This decomposition avoids "cross-world" counterfactuals (e.g., $L$4), making the resulting pathway estimates more interpretable and actionable for experimental or clinical interventions.

2. Identification Assumptions

Causal localization via these estimands requires the following identification assumptions:

1. Consistency: If $L$5 and $L$6, then the observed $L$7 equals $L$8.
2. Positivity: Every level of exposure and mediator has positive probability over all covariate strata.
3. No Unmeasured Confounding (Exchangeability):
   • $L$9 and $M_1,\ldots,M_K$0.
4. Manipulability of the Mediator: It must be possible (at least conceptually) to intervene on each mediator $M_1,\ldots,M_K$1 (Sun et al., 2020).

These conditions are implementable in experimental or well-controlled observational studies with measured confounding, but may require extensions or robustification in the presence of unmeasured confounding, high-dimensional mediators, or complex mediator-outcome relationships.

3. Estimation Strategies

Estimation is performed via doubly-robust procedures. The recommended workflow is:

• Model For Each Mediator: Fit $M_1,\ldots,M_K$2; e.g., logistic regression or random forest.
• Model For the Outcome: Fit $M_1,\ldots,M_K$3; e.g., penalized linear regression or boosting.
• Propensity Models: Obtain $M_1,\ldots,M_K$4 and $M_1,\ldots,M_K$5.
• Augmented Inverse Probability Weighting (AIPW):

$M_1,\ldots,M_K$6

$M_1,\ldots,M_K$7

• Plug into Definitions: Use these fitted values to compute $M_1,\ldots,M_K$8, $M_1,\ldots,M_K$9, and $K$0 per the identification formulas above.
• Cross-Fitting and Bootstrap: Cross-validated model selection and nonparametric bootstrap for uncertainty quantification (Sun et al., 2020).

This procedure provides robustness to model misspecification and mitigates finite-sample biases, provided at least one of the models is correctly specified.

4. Practical Workflow for Causal Localization

A principled localization workflow involves:

1. Causal DAG Specification: Construct a directed acyclic graph involving $K$1, $K$2, mediators $K$3, and outcome $K$4.
2. Confounder Control: For each mediator $K$5, adjust for all pre-exposure confounders $K$6 of both $K$7 and $K$8.
3. Estimate Path-Specific Effects:
   • Compute $K$9 under $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$0 to assess the effect of intervening on $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$1.
   • Compute $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$2 to measure the residual direct effect of $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$3 once $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$4 is fixed at baseline.
   • Localize the total effect using $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$5.
4. Rank and Prioritize: Rank mediators by $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$6 or $\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$7 to identify targets for potential intervention.
5. Experimental Validation: Design mediator-targeted interventions or encouragement designs to empirically test predicted pathway effects (Sun et al., 2020).

This approach is especially practical in systems where joint manipulation of all mediators is infeasible but single-mediator interventions are realistic.

5. Applications and Empirical Examples

The methodology has been applied in both simulated and real-world settings:

• Simulated Data: Recovery of pathway-specific and total effects, with correct decomposition under scenarios of independent and dependent mediators.
• Social Science Example: In a "framing" experiment (K=2), negative emotion ($\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$8) and perceived harm ($\mathrm{TE} = \mathbb{E}[Y(1) - Y(0)],$9) were mediators for the treatment effect of framing on attitude. The decomposition yielded $Y(a)$0 and $Y(a)$1 of the total effect, demonstrating that emotion is a quantitatively stronger mediator in that context.
• Clinical Cohort Example: In the HIV–Brain Age cohort (K=3), hyperlipidemia was identified as the dominant mediator ($Y(a)$2) through the largest $Y(a)$3. This suggested that interventions targeting hyperlipidemia could yield the most substantial reduction in the adverse outcome (brain-age) (Sun et al., 2020).

The framework thus provides actionable, interpretable, and empirically testable localization of causal pathways for prioritizing interventions.

6. Advantages and Scientific Relevance

Causal localization via controlled indirect effect analysis offers several advantages:

• Avoids Cross-World Counterfactuals: All estimands correspond to physically realizable interventions and do not rely on impossible or logically inconsistent reference states.
• Accommodates Arbitrary Mediator Dependencies: The decomposition remains valid even when mediators have arbitrary causal relationships among each other.
• Single-Mediator Manipulability: The clinical or operational feasibility of the approach is enhanced by focusing on interventions on one mediator at a time, circumventing the curse of dimensionality and interpretational ambiguities associated with joint manipulation.
• Guides Pathway-Specific Intervention Design: By quantifying the effect size attributable to each mediator, the framework provides a rational basis for prioritizing experimental efforts and resource allocation (Sun et al., 2020).

This methodology sharply contrasts with methods that decompose effects only under joint manipulation or require stringent assumptions about underlying mediator interactions. The approach is particularly suited to biomedical and social science contexts where direct, pathway-specific identification and intervention is of paramount importance.